| Document |
Document Title |
|
WO/2022/211052A1 |
The present invention relates to a therapeutic agent for a gait disturbance of a patient associated with an ischemic disease, the therapeutic agent containing, as an active ingredient, a heterocyclic derivative represented by general for...
|
|
WO/2022/211303A1 |
A 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative according to the present invention promotes the expression of the myogenic factors MyoG and MyHC while inhibiting the expression of the muscle atrophy factor atrogin-1, promotes the fo...
|
|
WO/2022/208256A1 |
The use of cholecalciferol is described as an active agent or adjuvant in muscle regeneration and in the protection of muscle tissue in subjects suffering from muscular dystrophies. Also described are pharmaceutical compositions or food ...
|
|
WO/2022/210802A1 |
The purpose of the present invention is to provide a novel agent for the prevention or treatment of muscular atrophy. The present invention provides an agent for the prevention or treatment of muscular atrophy, wherein the agent contains...
|
|
WO/2022/204955A1 |
A method for preparing exosomes derived from iPSCs or iPSC-derived cells, comprising: (i) culturing the iPSCs or iPSC-derived cells in a culture medium; (ii) obtaining a cell culture containing a first supernatant and adherent cells when...
|
|
WO/2022/211396A1 |
The present invention relates to a composition including a Salvia plebeia R. Br. extract or its derived compound rosmarinic acid and/or hispidulin as an active ingredient for prevention, palliation, or treatment of muscular dystrophy. Th...
|
|
WO/2022/212902A1 |
The present disclosure relates generally to therapeutic agents that may be useful as modulators of Integrated Stress Response (ISR) pathway.
|
|
WO/2022/210574A1 |
Provided is an agent for treating muscular dystrophy that can be easily manufactured and that has a high therapeutic effect. A cell population containing mesenchymal cells derived from amniotic tissue is compounded as an active ingredi...
|
|
WO/2022/208091A1 |
The present invention is directed to a polypeptide for use in treating pain or an inflammatory disorder, wherein the polypeptide comprises a clostridial neurotoxin light-chain (L-chain), a clostridial neurotoxin translocation domain (HN ...
|
|
WO/2022/211060A1 |
The purpose of the present invention is to provide a medicine for the prevention and/or treatment of a disease associated with ABHD6, which contains a compound having an ABHD6-inhibiting activity as an active ingredient. A compound repre...
|
|
WO/2022/200857A1 |
The present disclosure relates to a. compound of formula I or a. pharmaceutically acceptable salt thereof Formula I wherein A is Formula II X1 is linear or branched C1-6 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, 4-8 m...
|
|
WO/2022/202761A1 |
[Problem] To provide a peptide complex capable of binding to c-Met protein. [Solution] Provided is a peptide complex containing a peptide A, in which the peptide A is a peptide comprising the amino acid sequence represented by X1-X2-X3-V...
|
|
WO/2022/202403A1 |
Provided is a material that is useful for increasing the Neisseria mucosa content in the oral cavity. This oral Neisseria-mucosa-increasing agent has, as active ingredients, a nitrate-ion-supplying compound and one or more sugar alcoho...
|
|
WO/2022/198438A1 |
Disclosed are ligand-bound zinc sulfide nanoparticles, the method of preparing the ligand-bound zinc sulfide nanoparticles, composition containing ligand-bound zinc sulfide nanoparticles, uses of ligand-bound zinc sulfide nanoparticles a...
|
|
WO/2022/203131A1 |
The present invention relates to a pharmaceutical composition containing oyster hydrolysate as an active ingredient for preventing or treating muscle diseases. The oyster hydrolysate of the present invention lessens the reduction in musc...
|
|
WO/2022/204683A1 |
Disclosed herein are quinazolinyl compounds, compositions, and methods of use thereof. The compounds may be used in the treatment of kinase-related disorders (including cancer, autoimmune disease, and Duchenne muscular dystrophy).
|
|
WO/2022/203130A1 |
The present invention relates to a health food composition containing oyster hydrolysate as an active ingredient for preventing muscle diseases or improving muscle function. The oyster hydrolysate of the present invention lessens the red...
|
|
WO/2022/195451A1 |
Redox-active compound or a pharmaceutically acceptable salt thereof for use in the method for treating a disease selected from among the diseases due to dysfunction of the mitochondrial respiratory chain complexes I, II, III. This redox-...
|
|
WO/2022/196719A1 |
The present invention provides: a chimeric receptor polypeptide which is useful in treatment of myasthenia gravis and in which an extracellular domain that includes an antigenic region linkable to an anti-human nicotinic acetylcholine re...
|
|
WO/2022/198114A1 |
Prodrugs of pharmacologically active 1,2,4-triaminobenzene derivatives of the General Formula (I); or pharmaceutically acceptable salts thereof, where the symbols R1, R2, R3, R4, R5 and R6a, R6b, and R6c and where the symbol Z are define...
|
|
WO/2022/196683A1 |
Disclosed is a serum albumin-thioredoxin fusion body which is improved in the activity thereof and is stable with respect to the activity. A serum albumin-thioredoxin fusion body is provided, which is characterized in that the thioredoxi...
|
|
WO/2022/197857A1 |
Described herein are compositions and methods that can be used to contract nucleotide repeat expansion (e.g., CGG) in a gene (e.g., FMR1) in cells of subjects having a condition associated with nucleotide repeat expansion, e.g., subjects...
|
|
WO/2022/198115A1 |
Prodrugs of pharmacologically active 1,2,4-triaminobenzene derivatives of the General Formula (I); or pharmaceutically acceptable salts thereof, where the symbols R1, R2, R3, R4, R5 and R6a, R6b, and R6c and where the symbol Z are define...
|
|
WO/2022/188029A1 |
A compound powder/granule containing tauroursodeoxycholic acid and sodium phenylbutyrate, comprising raw materials of sodium phenylbutyrate, tauroursodeoxycholic acid, a lubricant, a glidant, a flavoring agent, etc. The present applicati...
|
|
WO/2022/192562A1 |
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of USP30, and the treatment of USP30-mediated disorders.
|
|
WO/2022/191306A1 |
The present disclosure provides a pharmaceutical composition for the treatment or prevention of myasthenia gravis, having as an active ingredient satralizumab.
|
|
WO/2022/187571A1 |
The disclosure relates to the field of gene therapy for the treatment of a muscular dystrophy including, but not limited to, Duchenne's muscular dystrophy (DMD), Becker's muscular dystrophy (BMD), or intermediate muscular dystrophy (IMD)...
|
|
WO/2022/187543A1 |
Compositions and methods are provided for treating myopathies by administering a complex formed between a therapeutic mRNA polynucleotide and a 3E10 antibody or variant thereof, or antigen-binding fragment thereof. In some instances, the...
|
|
WO/2022/186658A1 |
The present invention relates to a composition for preventing, alleviating or treating sarcopenia, containing D-ribo-2-hexulose as an active ingredient. D-ribo-2-hexulose of the present invention is a sweetener capable of replacing sugar...
|
|
WO/2022/184018A1 |
An exogenous mitochondria vector, a complex, and a preparation method therefor and the use thereof. Specifically, an ex vivo exogenous mitochondria is modified by one or more materials with a good biocompatibility, the modified ex vivo e...
|
|
WO/2022/183281A1 |
Among other things, in general, compositions and methods of treatment for muscular dystrophy and other diseases are disclosed. A method of treatment of a subject is disclosed, in which fatty acid utilization is improved. The method inclu...
|
|
WO/2022/181532A1 |
Provided is a method for inhibiting the function of myostatin. Provided are: an antisense oligonucleotide having a base length of 15-30 and a base sequence complementary to the target sequence of exon 3 of myostatin gene, the antisense o...
|
|
WO/2022/181936A1 |
The present invention relates to a composition that increases the level of microRNA-26a in extracellular vesicles and uses thereof. The composition increases the level of microRNA-26a (miRNA-26a) in exosomes secreted from cells, and the ...
|
|
WO/2022/180116A1 |
Composition comprising a combination of oleuropein or metabolite thereof and Vitamin B6 thereof are provided. The composition may be an oral nutritional composition, for example a nutritional supplement, an oral nutritional supplement, a...
|
|
WO/2022/177236A1 |
The present invention relates to a pharmaceutical composition for preventing or treating muscular atrophy or cachexia, comprising an extract containing ginseng-derived gintonin, a fraction thereof, or gintonin, as an active ingredient.
|
|
WO/2022/175478A1 |
The invention relates to inhibitors of MSI2 functions that are able to decrease MSI2 activity, MSI2 transcript levels or MSI2 protein levels in myotonic dystrophy cells or cells with MD phenotype, wherein said inhibitor is for use in the...
|
|
WO/2022/178273A1 |
Provided herein, in some embodiments, are nucleic acid constructs encoding therapeutic proteins of interest comprising one or more alternatively-spliced exons that regulate the expression of therapeutic proteins of interest. Such constru...
|
|
WO/2022/176859A1 |
The present invention aims to provide a novel therapeutic approach to human muscular dystrophy (particularly MDC1A). The present invention provides a polynucleotide comprising the following base sequences: (a) a base sequence encoding a ...
|
|
WO/2022/177267A1 |
The present invention relates to a compound for suppressing nonsense-mediated mRNA decay (hereinafter referred to as "NMD") and a pharmaceutically acceptable salt thereof. The present invention aims to prevent or treat NMD-related diseas...
|
|
WO/2022/176677A1 |
Provided is a novel material that exhibits a superior effect for muscle enhancement using a fatty acid. The present invention is a composition for muscle enhancement characterized by containing, as an active component, at least one sub...
|
|
WO/2022/177116A1 |
The present invention relates to a composition for preventing, ameliorating, or treating muscle strengthening, muscle building, muscle differentiation, muscle regeneration, muscle loss, or muscle fatigue, comprising a Schizonepeta tenuif...
|
|
WO/2022/177313A1 |
The present invention relates to a sesquiterpene derivative or a pharmaceutically acceptable salt thereof, a composition for preventing, ameliorating or treating sarcopenia, comprising the derivative or salt thereof as an active ingredie...
|
|
WO/2022/177269A1 |
The present invention relates to a compound for inhibiting nonsense-mediated mRNA decay (hereinafter referred to as "NMD") or a pharmaceutically acceptably salt thereof. The present invention aims to prevent or treat an NMD-related disea...
|
|
WO/2022/177740A1 |
Compounds and compositions that deliver both uridine and ketoleucine are useful in treating disorders characterized by diminished muscle strength or diminished muscle lean mass. One such a compound is 5 ' -O-ketoleucyl-2',3 ' -di-O-acety...
|
|
WO/2022/173123A1 |
The present invention relates to a composition for preventing or treating sarcopenia or osteoporosis, comprising cyclo-L-phenylalanyl-L-proline dipeptides. The composition for preventing or treating sarcopenia or osteoporosis, comprising...
|
|
WO/2022/171972A1 |
Disclosed are conjugates of an oligonucleotide and a peptide covalently bonded or linked via a linker to the oligonucleotide, the peptide including at least one cationic domain comprising at least 4 amino acid residues and at least one h...
|
|
WO/2022/172019A1 |
Disclosed are conjugates of an oligonucleotide and a peptide covalently bonded or linked via a linker to the oligonucleotide, the peptide including at least one cationic domain comprising at least 4 amino acid residues and at least one h...
|
|
WO/2022/173273A1 |
The present invention relates to a composition for prophylaxis, amelioration, or treatment purposes for muscular diseases, comprising an aronia extract. The composition strengthens muscles through promotion of differentiation of myoblast...
|
|
WO/2022/168008A1 |
The present disclosure includes the use of miRNA inhibitor for treating a disease or condition associated with a decreased level of PSD95 and/or synaptophysin and/or an increased level of caspase 3 (e.g., dystonia, neuropsychiatric disea...
|
|
WO/2022/169922A1 |
Disclosed herein are products, methods, and uses for treating, ameliorating, delaying the progression of, and/or preventing a muscular dystrophy or a cancer including, but not limited to, facioscapulohumeral muscular dystrophy (FSHD) or ...
|
